PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY - PALISADE

Aimmune Therapeutics, Inc.0 个研究点目标入组 500 人开始时间: 2017年3月7日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1. Completion of ARC003
•2. Written informed consent and/or assent from subjects/guardians as appropriate
•3. Use of effective birth control by female subjects of child-bearing potential
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 400
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Early discontinuation from ARC003
•2. Meets any longitudinally applicable ARC003 exclusion criteria
•3. Failure to tolerate > or = 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 Exit DBPCFC (Group 2 only)
•4. Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety

发起方